Literature DB >> 10742135

Monoclonal antibody therapies-a 'constant' threat to cancer.

A N Houghton, D A Scheinberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10742135     DOI： 10.1038/74621

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology.

Authors:  Christine Solbach; Anja Sterner-Kock; Marc Roller; Hans Georg Schnürch; Manfred Stegmüller; Gudrun Caspar-Bell; Petra Maria Schumm-Draeger; Manfred Kaufmann; Rainald Knecht
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.

Authors:  Miao Wang; Shuai Zhang; Qian Sun; Xiangmin Yang; Yu Wang; Runze Shang; Yumeng Zhu; Hui Yao; Yu Li
Journal:  Cancer Biol Ther       Date:  2019-08-14       Impact factor: 4.742

3.  Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.

Authors:  Veronika Groh; Yongqing Q Li; Daniel Cioca; Naomi N Hunder; Wei Wang; Stanley R Riddell; Cassian Yee; Thomas Spies
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-11       Impact factor: 11.205

4.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Authors:  Danila Valmori; Naira E Souleimanian; Valeria Tosello; Nina Bhardwaj; Sylvia Adams; David O'Neill; Anna Pavlick; Juliet B Escalon; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Gregory Mears; Susan M Vogel; Linda Pan; Achim A Jungbluth; Eric W Hoffmann; Ralph Venhaus; Gerd Ritter; Lloyd J Old; Maha Ayyoub
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

Review 5.  Immunological ignorance of solid tumors.

Authors:  Adrian F Ochsenbein
Journal:  Springer Semin Immunopathol       Date:  2005-01-27

6.  Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.

Authors:  Kavita M Dhodapkar; Joseph Krasovsky; Barbara Williamson; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

7.  Fc gamma receptors and cross-presentation in dendritic cells.

Authors:  Sebastian Amigorena
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

8.  Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Authors:  N E Annels; G R Simpson; M Denyer; S E McGrath; G Falgari; E Killick; R Eeles; J Stebbing; D Pchejetski; R Cutress; N Murray; A Michael; H Pandha
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

9.  Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Authors:  R Repp; H H van Ojik; T Valerius; G Groenewegen; G Wieland; C Oetzel; B Stockmeyer; W Becker; M Eisenhut; H Steininger; Y M Deo; G H Blijham; J R Kalden; J G J van de Winkel; M Gramatzki
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

Review 10.  The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials.

Authors:  Jin Sheng; Yun-Peng Yang; Yuan-Yuan Zhao; Tao Qin; Zhi-Huang Hu; Ting Zhou; Ya-Xiong Zhang; Shao-Dong Hong; Yu-Xiang Ma; Hong-Yun Zhao; Yan Huang; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.